Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Debt to Equity (2016 - 2026)

Heron Therapeutics filings provide 6 years of Debt to Equity readings, the most recent being $11.85 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 1437.69% to $11.85 in Q1 2026 year-over-year; TTM through Mar 2026 was $11.85, a 1437.69% increase, with the full-year FY2025 number at $7.53, up 1112.25% from a year prior.
  • Debt to Equity hit $11.85 in Q1 2026 for Heron Therapeutics, up from $7.53 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $11.85 in Q1 2026 to a low of -$0.89 in Q1 2025.
  • Median Debt to Equity over the past 4 years was -$0.68 (2024), compared with a mean of $2.14.
  • Biggest five-year swings in Debt to Equity: decreased 22.39% in 2025 and later skyrocketed 1437.69% in 2026.
  • Heron Therapeutics' Debt to Equity stood at -$0.71 in 2023, then fell by 4.13% to -$0.74 in 2024, then surged by 1112.25% to $7.53 in 2025, then skyrocketed by 57.46% to $11.85 in 2026.
  • The last three reported values for Debt to Equity were $11.85 (Q1 2026), $7.53 (Q4 2025), and $7.22 (Q3 2025) per Business Quant data.